These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26987390)

  • 1. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial.
    Kim YE; Joo B; Park MS; Shin SJ; Ahn JB; Kim MJ
    Cancer Res Treat; 2016 Oct; 48(4):1210-1221. PubMed ID: 26987390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
    Hirashima Y; Yamada Y; Tateishi U; Kato K; Miyake M; Horita Y; Akiyoshi K; Takashima A; Okita N; Takahari D; Nakajima T; Hamaguchi T; Shimada Y; Shirao K
    Int J Cancer; 2012 May; 130(10):2359-65. PubMed ID: 21780098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker
    Van Cutsem E; Paccard C; Chiron M; Tabernero J
    Clin Cancer Res; 2020 Feb; 26(3):717-725. PubMed ID: 31727675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
    Morgan B; Thomas AL; Drevs J; Hennig J; Buchert M; Jivan A; Horsfield MA; Mross K; Ball HA; Lee L; Mietlowski W; Fuxuis S; Unger C; O'Byrne K; Henry A; Cherryman GR; Laurent D; Dugan M; Marmé D; Steward WP
    J Clin Oncol; 2003 Nov; 21(21):3955-64. PubMed ID: 14517187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dynamic Contrast-enhanced Magnetic Resonance Imaging Permeability Parameters Monitor the Early Response to Bevacizumab Plus Chemotherapy in Colorectal Cancer Patients with Liver Metastases].
    Liu D; Qian HF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Apr; 40(2):256-263. PubMed ID: 29724317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma.
    Sweis RF; Medved M; Towey S; Karczmar GS; Oto A; Szmulewitz RZ; O'Donnell PH; Fishkin P; Karrison T; Stadler WM
    Clin Genitourin Cancer; 2017 Apr; 15(2):207-212. PubMed ID: 27634566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial.
    Lebellec L; Bertucci F; Tresch-Bruneel E; Ray-Coquard I; Le Cesne A; Bompas E; Blay JY; Italiano A; Mir O; Ryckewaert T; Toiron Y; Camoin L; Goncalves A; Penel N; Le Deley MC
    BMC Cancer; 2018 Oct; 18(1):963. PubMed ID: 30305054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-angiogenic therapy with contrast-enhanced ultrasound in colorectal cancer patients with liver metastasis.
    Wu Z; Yang X; Chen L; Wang Z; Shi Y; Mao H; Dai G; Yu X
    Medicine (Baltimore); 2017 May; 96(20):e6731. PubMed ID: 28514289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.
    Carbone C; Piro G; Simionato F; Ligorio F; Cremolini C; Loupakis F; Alì G; Rossini D; Merz V; Santoro R; Zecchetto C; Zanotto M; Di Nicolantonio F; Bardelli A; Fontanini G; Tortora G; Melisi D
    Clin Cancer Res; 2017 Aug; 23(15):4312-4322. PubMed ID: 28298545
    [No Abstract]   [Full Text] [Related]  

  • 10. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
    Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
    Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
    Yopp AC; Schwartz LH; Kemeny N; Gultekin DH; Gönen M; Bamboat Z; Shia J; Haviland D; D'Angelica MI; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR
    Ann Surg Oncol; 2011 Aug; 18(8):2192-9. PubMed ID: 21286939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
    Hahn OM; Yang C; Medved M; Karczmar G; Kistner E; Karrison T; Manchen E; Mitchell M; Ratain MJ; Stadler WM
    J Clin Oncol; 2008 Oct; 26(28):4572-8. PubMed ID: 18824708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
    Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
    Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer.
    Bai L; Wang F; Zhang DS; Li C; Jin Y; Wang DS; Chen DL; Qiu MZ; Luo HY; Wang ZQ; Li YH; Wang FH; Xu RH
    Sci Rep; 2015 Dec; 5():17717. PubMed ID: 26620439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab.
    Hara M; Nagasaki T; Shiga K; Takahashi H; Takeyama H
    Surg Today; 2017 Apr; 47(4):483-489. PubMed ID: 27549777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy.
    Ravanelli M; Agazzi GM; Tononcelli E; Roca E; Cabassa P; Baiocchi G; Berruti A; Maroldi R; Farina D
    Radiol Med; 2019 Sep; 124(9):877-886. PubMed ID: 31172448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed-effects modeling of clinical DCE-MRI data: application to colorectal liver metastases treated with bevacizumab.
    Ferl GZ; O'Connor JP; Parker GJ; Carano RA; Acharya SJ; Jayson GC; Port RE
    J Magn Reson Imaging; 2015 Jan; 41(1):132-41. PubMed ID: 24753433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab.
    Garde-Noguera J; Gil-Raga M; Evgenyeva E; García JA; Llombart-Cussac A; Camps-Herrero C
    Clin Transl Oncol; 2016 Apr; 18(4):405-12. PubMed ID: 26307753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.